Published in Arch Intern Med on June 01, 1978
Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrob Agents Chemother (1980) 3.54
Neonatal sepsis caused by Streptococcus bovis variant (biotype II/2): report of a case and review. J Clin Microbiol (2003) 1.07
Penicillin therapy of experimental endocarditis induced by tolerant Streptococcus sanguis and nontolerant Streptococcus mitis. Antimicrob Agents Chemother (1983) 0.88
Screening of Neisseria gonorrhoeae for tolerant response to beta-lactam antibiotics. Antimicrob Agents Chemother (1981) 0.88
Serum bactericidal test. Clin Microbiol Rev (1988) 0.86
Incidence of penicillin tolerance among blood culture isolates of Streptococcus sanguis, 1987-88. J Clin Pathol (1991) 0.81
Metachromatic agar-diffusion methods for detecting staphylococcal nuclease activity. Appl Microbiol (1971) 10.60
An improved single-disk method for testing the antibiotic susceptibility of rapidly-growing pathogens. Am J Clin Pathol (1970) 8.90
Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study. J Clin Microbiol (1981) 8.49
Evaluation of the micro-media system for quantitative antimicrobial drug susceptibility testing: a collaborative study. Antimicrob Agents Chemother (1978) 8.08
Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis (1972) 7.47
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother (1995) 5.74
Evaluation of the Sensititre system for quantitative antimicrobial drug susceptibility testing: a collaborative study. Antimicrob Agents Chemother (1980) 5.34
Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1994) 5.33
Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1979) 5.10
In-vitro methods for determining minimal lethal concentrations of antimicrobial agents. Am J Clin Pathol (1979) 4.66
Rapid determination of antimicrobial susceptibility for urgent clinical situations. Am J Clin Pathol (1973) 4.18
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother (1984) 4.13
Reliability of the microdilution technic for detection of methicillin-resistant strains of staphylococcus aureus. Am J Clin Pathol (1977) 4.02
Evaluation of the Sceptor microdilution antibiotic susceptibility testing system: a collaborative investigation. J Clin Microbiol (1981) 3.86
Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole. J Clin Microbiol (1994) 3.77
In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs. Antimicrob Agents Chemother (1983) 3.70
Identification of Staphylococcus aureus by simultaneous use of tube coagulase and thermonuclease tests. Appl Microbiol (1973) 3.70
Reliability of the Kirby-Bauer disc diffusion method for detecting methicillin-resistant strains of Staphylococcus aureus. Appl Microbiol (1972) 3.55
Evaluation of the sensititre microdilution antibiotic susceptibility system against recent clinical isolates: three-laboratory collaborative study. J Clin Microbiol (1980) 3.49
Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother (1987) 3.47
Nuclease production and lysostaphin susceptibility of Staphylococcus aureus and other catalase-positive cocci. Appl Microbiol (1971) 3.40
Rapid identification of Enterobacteriaceae with the micro-ID system versus API 20E and conventional media. J Clin Microbiol (1979) 3.17
Short-term storage of six penicillins and cephalothin in microdilution trays for antimicrobial susceptibility tests. Antimicrob Agents Chemother (1976) 3.12
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrob Agents Chemother (1984) 3.04
Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin. Antimicrob Agents Chemother (1980) 2.92
In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin. Antimicrob Agents Chemother (1984) 2.73
Evaluation of teicoplanin and vancomycin disk susceptibility tests. J Clin Microbiol (1986) 2.61
Identification of Enterobacteriaceae in frozen microdilution trays prepared by Micro-Media Systems. J Clin Microbiol (1979) 2.49
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1985) 2.48
In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin. Antimicrob Agents Chemother (1981) 2.45
Gentamicin therapy in renal failure: a nomogram for dosage. Ann Intern Med (1972) 2.43
Interpretive standards and quality control guidelines for imipenem susceptibility tests with 10-micrograms disks. J Clin Microbiol (1984) 2.40
Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester. J Infect Dis (1976) 2.31
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother (1991) 2.26
Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test. J Clin Microbiol (1996) 2.23
Diagnostic usefulness and safety of transtracheal aspiration. N Engl J Med (1967) 2.23
Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin. Antimicrob Agents Chemother (1980) 2.20
Efficiency of a transport medium for the recovery of aerobic and anaerobic bacteria from applicator swabs. Appl Microbiol (1972) 2.13
Rapid ornithine decarboxylase test for the identification of enterobacteriaceae. Appl Microbiol (1972) 2.11
Susceptibility of three groups of Staphylococcus aureus to newer antimicrobial agents. Antimicrob Agents Chemother (1977) 2.09
Cefuroxime, an in vitro Comparison with Six Other Cephalosporins. Proc R Soc Med (1977) 2.06
Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates. Antimicrob Agents Chemother (1977) 2.04
Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing. Antimicrob Agents Chemother (1980) 2.03
Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitin. J Antibiot (Tokyo) (1977) 2.01
BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins. J Antibiot (Tokyo) (1977) 2.00
In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother (1990) 1.98
In-vitro studies of meropenem. J Antimicrob Chemother (1989) 1.96
Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965). J Clin Microbiol (1986) 1.93
Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination. J Clin Microbiol (1987) 1.89
Reader error in determining minimal inhibitory concentrations with microdilution susceptibility test panels. J Clin Microbiol (1981) 1.84
Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing. Diagn Microbiol Infect Dis (1983) 1.83
Problems in the diagnosis and treatment of systemic candidiasis. J Infect Dis (1972) 1.83
Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis (2000) 1.82
Miconazole therapy for coccidioidomycosis. JAMA (1974) 1.81
Cefixime disk susceptibility test criteria. J Clin Microbiol (1986) 1.79
Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin. J Antimicrob Chemother (1997) 1.79
Penetration of antimicrobial agents into bronchial secretions. Am J Med (1975) 1.74
Piperacillin susceptibility tests by the single-disk agar diffusion technique. Antimicrob Agents Chemother (1979) 1.73
Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests. J Clin Microbiol (1987) 1.71
In vitro activity and disk susceptibility of Timentin: current status. Am J Med (1985) 1.70
Sensitivity, specificity, and reproducibility of the automicrobic system (with the Enterobacteriaceae-plus biochemical card) for identifying clinical isolates of Gram- negative bacilli. J Clin Microbiol (1982) 1.69
Four-hour urease test for distinguishing between Klebsiella and Enterobacter. Appl Microbiol (1969) 1.68
Accuracy and precision of the autobac system for rapid identification of Gram-negative bacilli: a collaborative evaluation. J Clin Microbiol (1982) 1.68
Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic. J Clin Microbiol (1990) 1.67
A simple, rapid test to differentiate penicillin-susceptible from penicillin-resistant Staphylococcus aureus. J Infect Dis (1970) 1.66
In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits. Antimicrob Agents Chemother (1983) 1.66
Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing. Antimicrob Agents Chemother (1982) 1.64
Identification of Enterobacteriaceae by the automicrobic system: Enterobacteriaceae biochemical cards versus Enterobacteriaceae-plus biochemical cards. J Clin Microbiol (1982) 1.62
Rosamicin: in vitro activity comparison with erythromycin and other antibiotics against clinical isolates from the genito-urinary tract and Neisseria meningitidis. J Antibiot (Tokyo) (1979) 1.61
A system for reporting quantitative antimicrobic susceptibility test results. Am J Clin Pathol (1979) 1.59
Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid. J Clin Microbiol (1989) 1.58
Two quick methods for Voges-Proskauer test. Appl Microbiol (1967) 1.58
Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol (1990) 1.57
Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria. Antimicrob Agents Chemother (1981) 1.55
Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin. J Clin Microbiol (1991) 1.55
Prediction of antimeningococcic chemoprophylactic efficacy. J Infect Dis (1971) 1.55
In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use. Diagn Microbiol Infect Dis (1989) 1.53
Simple inoculum standardizing system for antimicrobial disk susceptibility tests. J Clin Microbiol (1979) 1.52
Comparison of amphotericin B and amphotericin B methyl ester: efficacy in murine coccidioidomycosis and toxicity. J Infect Dis (1976) 1.52
In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates. Antimicrob Agents Chemother (1984) 1.52
Reassessment of the "class" concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporins. Am J Clin Pathol (1978) 1.51
Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother (1989) 1.50
Susceptibility of coccidioides immitis, Candida albicans, and Cryptococcus neoformans to amphotericin B, flucytosine, and clotrimazole. J Infect Dis (1975) 1.50
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria. Diagn Microbiol Infect Dis (1986) 1.49
Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrob Agents Chemother (1988) 1.48
Ceftriaxone: a summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-micrograms disks. Diagn Microbiol Infect Dis (1983) 1.47
In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother (2001) 1.45
Effect of buffers on testing of Candida species susceptibility to flucytosine. J Clin Microbiol (1987) 1.44
Gentamicin and amikacin disk susceptibility tests with Pseudomonas aeruginosa: definition of minimal inhibitory concentration correlates for susceptible and resistant categories. J Clin Microbiol (1981) 1.44
Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy. Rev Infect Dis (1983) 1.43
Cefaclor and cefatrizine, new investigational orally administered cephalosporins. In-vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics. Am J Clin Pathol (1979) 1.43
Ticarcillin, carbenicillin and BL-P1908. In vitro comparison of three anti-pseudomonal semisynthetic penicillins. J Antibiot (Tokyo) (1977) 1.43
In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests. J Antimicrob Chemother (1999) 1.43
Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates. Clin Ther (1980) 1.43
Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. Rev Infect Dis (1983) 1.43
Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines. Eur J Clin Microbiol Infect Dis (1988) 1.41
Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods. J Clin Microbiol (1986) 1.40
Comparison of the antibacterial spectra of cephalexin and cefaclor with those of cephalothin and newer cephalosporins: reevaluation of the class representative concept of susceptibility testing. J Clin Microbiol (1983) 1.39
Chemotherapy of systemic fungal diseases. Annu Rev Pharmacol Toxicol (1978) 1.39